eTable 1. List of 29 solid tumor types or subtypes eTable 2. List of studies with anti-PD-1/PD-L1 monotherapy, anti-CTLA-4 monotherapy, and anti-PD-1/PD-L1 plus anti-CTLA-4 therapy eTable 3. Pooled response and toxicity rates for each tumor type within each treatment category (single: anti-PD-1/PD-L1; dual: anti-PD-1/PD-L1 plus anti- CTLA-4) eTable 4. Descriptive statistics of median overall survival for each tumor type within each treatment category (single: anti-PD-1/PD-L1, anti-CTLA-4; dual: anti-PD-1/PD-L1 plus anti-CTLA-4) eFigure 1. Forest plot of response rates among studies with anti-PD-1/PD-L1 monotherapy by tumor type eFigure 2. Forest plot of response rates among studies with anti-CTLA-4 monotherapy by tumor type eFigure 3. Forest plot of response rates among studies with anti-PD-1/PD-L1 plus anti-CLTA-4 therapy by tumor type eFigure 4. Forest plot of toxicity rates among studies with anti-PD-1/PD-L1 monotherapy by tumor type eFigure 5. Forest plot of toxicity rates among studies with anti-CTLA-4 monotherapy by tumor type eFigure 6. Forest plot of toxicity rates among studies with anti-PD-1/PD-L1 plus anti-CLTA-4 therapy by tumor type eFigure 7. Forest plot of hazard ratios for overall survival among studies with anti-PD-1/PD-L1 monotherapy
21
Embed
clincancerres.aacrjournals.org · Web vieweTable 1.List of 29 solid tumor types or subtypes eTable 2. List of studies with anti-PD-1/PD-L1 monotherapy, anti-CTLA-4 monotherapy, and
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
eTable 1. List of 29 solid tumor types or subtypes
eTable 2. List of studies with anti-PD-1/PD-L1 monotherapy, anti-CTLA-4 monotherapy, and anti-PD-1/PD-L1 plus anti-CTLA-4 therapy
eTable 3. Pooled response and toxicity rates for each tumor type within each treatment category (single: anti-PD-1/PD-L1; dual: anti-PD-1/PD-L1 plus anti-CTLA-4)
eTable 4. Descriptive statistics of median overall survival for each tumor type within each treatment category (single: anti-PD-1/PD-L1, anti-CTLA-4; dual: anti-PD-1/PD-L1 plus anti-CTLA-4)
eFigure 1. Forest plot of response rates among studies with anti-PD-1/PD-L1 monotherapy by tumor type
eFigure 2. Forest plot of response rates among studies with anti-CTLA-4 monotherapy by tumor type
eFigure 3. Forest plot of response rates among studies with anti-PD-1/PD-L1 plus anti-CLTA-4 therapy by tumor type
eFigure 4. Forest plot of toxicity rates among studies with anti-PD-1/PD-L1 monotherapy by tumor type
eFigure 5. Forest plot of toxicity rates among studies with anti-CTLA-4 monotherapy by tumor type
eFigure 6. Forest plot of toxicity rates among studies with anti-PD-1/PD-L1 plus anti-CLTA-4 therapy by tumor type
eFigure 7. Forest plot of hazard ratios for overall survival among studies with anti-PD-1/PD-L1 monotherapy
eTable 1. List of 29 solid tumor types or subtypes
Anal Cancer Germ Cell Tumor Other MSIBiliary Tract Cancer Glioblastoma Ovarian CancerBladder Cancer Head and Neck Pancreatic Cancer
Breast Carcinoma Hepatocellular Carcinoma Prostate Cancer
Cervical Cancer Melanoma Renal Cell Carcinoma
Colorectal Cancer – MSI Merkel Cell Carcinoma Sarcoma
Colorectal Cancer – MSS Mesothelioma Small Cell Lung Cancer
Cutaneous Squamous Cell Carcinoma Nasopharyngeal ThymicEndometrial Cancer Non-Small Cell Lung Cancer
eTable 2. List of studies with anti-PD-1/PD-L1 monotherapy, anti-CTLA-4 monotherapy, and anti-PD-1/PD-L1 plus anti-CTLA-4 therapy
List of studies with anti-PD-1/PD-L1 monotherapyFirst Author Journal Year Drug General Tumor TypeLe Tourneau Annals of Oncology 2017 Avelumab Adrenocortical CarcinomaMorris Lancet Oncology 2017 Nivolumab Anal Cancer
Ioka Journal of Clinical Oncology 2019 Durvalumab Biliary Tract CancerKim Annals of Oncology 2018 Nivolumab Biliary Tract Cancer
Ueno Annals of Oncology 2018 Pembrolizumab Biliary Tract CancerRosenberg Lancet 2016 Atezolizumab Bladder Cancer
Apolo Journal of Clinical Oncology 2017 Avelumab Bladder CancerPowles JAMA Oncology 2017 Durvalumab Bladder Cancer
Sharma Lancet Oncology 2017 Nivolumab Bladder CancerBellmunt The New England Journal of
Medicine2017 Pembrolizumab Bladder Cancer
Schmid Cancer Research 2017 Atezolizumab Breast Carcinoma
Dirix Breast Cancer Research and Treatment
2018 Avelumab Breast Carcinoma
Rischin Annals of Oncology 2018 Cemiplimab Cervical CancerSantin Journal of Clinical Oncology 2018 Nivolumab Cervical Cancer
Chung Journal of Clinical Oncology 2018 Pembrolizumab Cervical CancerOverman Journal of Clinical Oncology 2018 Nivolumab Colorectal Cancer – MSI
Le Annals of Oncology 2018 Pembrolizumab Colorectal Cancer – MSIEng Lancet 2019 Atezolizumab Colorectal Cancer – MSS
Brahmer Journal of Clinical Oncology 2010 Nivolumab Colorectal Cancer – MSSLe The New England Journal of
Medicine2015 Pembrolizumab Colorectal Cancer – MSS
Sequist Annals of Oncology 2016 Atezolizumab Small Cell Lung CancerReck Annals of Oncology 2018 Nivolumab Small Cell Lung Cancer
Chung Journal of Clinical Oncology 2018 Pembrolizumab Small Cell Lung CancerSeto Journal of Thoracic Oncology 2018 Nivolumab Thymic
Giaccone Journal of Clinical Oncology 2017 Pembrolizumab Thymic
Algazi Cancer 2016 anti-PD-1/anti-PD-L1
Ocular/Uveal melanoma
Namikawa Annals of Oncology 2017 Nivolumab Ocular/Uveal melanoma
List of studies with anti-CTLA-4 monotherapyFirst Author Journal Year Drug General Tumor TypeLheureux Journal of Clinical Oncology 2017 Ipilimumab Cervical Cancer
Chung Journal of Clinical Oncology 2010 Tremelimumab Colorectal Cancer – MSSBang Clinical Cancer Research 2017 Ipilimumab Esophagogastric Carcinoma
Ralph Clinical Cancer Research 2010 Tremelimumab Esophagogastric CarcinomaSangro Journal of Hepatology 2013 Tremelimumab Hepatocellular Carcinoma
Zatloukal Journal of Clinical Oncology 2016 Tremelimumab Non-Small Cell Lung CancerJoshua Melanoma Research 2015 Tremelimumab Ocular/Uveal melanoma
Le Journal of Immunotherapy 2014 Ipilimumab Pancreatic CancerSharma Journal of Clinical Oncology 2018 Tremelimumab Pancreatic Cancer
Slovin Annals of Oncology 2013 Ipilimumab Prostate CancerYang Journal of Immunotherapy 2007 Ipilimumab Renal Cell Carcinoma
List of studies with anti-PD-1/PD-L1 plus anti-CTLA-4 therapyFirst Author Journal Year Drug General Tumor TypeIoka Journal of Clinical Oncology 2019 Durva/Treme Biliary Tract CancerBalar Cancer Research 2018 Durva/Treme Bladder Cancer
Rosenberg Annals of Oncology 2018 Ipi/Nivo Bladder CancerSanta-Maria Journal of Clinical Oncology 2017 Durva/Treme Breast Carcinoma
Callahan Journal of Clinical Oncology 2017 Durva/Treme Cervical CancerOverman Journal of Clinical Oncology 2018 Ipi/Nivo Colorectal Cancer – MSI
Chen Journal of Clinical Oncology 2019 Durva/Treme Colorectal Cancer – MSSJanjigian Journal of Clinical Oncology 2018 Ipi/Nivo Esophagogastric Carcinoma
Cho Journal of Clinical Oncology 2018 Durva/Treme Small Cell Lung CancerHellmann Journal of Clinical Oncology 2017 Ipi/Nivo Small Cell Lung Cancer
eTable 3. Pooled response and toxicity rates for each tumor type within each treatment category (single: anti-PD-1/PD-L1; dual: anti-PD-1/PD-L1 plus anti-CTLA-4)
Response Rate Toxicity Rate
General Tumor Type TMB (median) Single Dual Difference Single Dual Difference
eTable 4. Descriptive statistics of median overall survival for each tumor type within each treatment category (single: anti-PD-1/PD-L1, anti-CTLA-4; dual: anti-PD-1/PD-L1 plus anti-CTLA-4)
General Tumor Type TMB(median)
Statistics Anti-PD-1/PD-L1 Monotherapy
Anti-CTLA-4 Monotherapy
Anti-PD-1/PD-L1 plus anti-CTLA-4
TherapyOcular/Uveal melanoma 1.30 Num. of Studies 2 1 1